مباشر

IlluminaIllumina stock (US4523271090): Corporate Responsibility Report highlights genomics growth drivers - AD HOC NEWS PfizerPharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters FierceBiotechGHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm Clinical OMICsEarly Medical Care Linked to Rapid Gut Microbiome Shifts in Amazonian Indigenous Communities Clinical OMICsAI Shows Value for Breast Cancer Prediction Merck & Co.EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView FierceBiotechQiagen links with chip giant Nvidia to propel AI use in drug discovery Clinical OMICsMolecular Imaging Could Detect Early Kidney Fibrosis Clinical OMICsUltra-Short Radiotherapy Schedule for Prostate Cancer Supported by HERMES Trial Endpoints NewsI&I biotech cAMPfield attracts top-tier investors in $180M Series A PfizerPfizer takes 25-valent Prevnar follow-up into phase 3 - pharmaphorum Clinical OMICsMYC Protein Linked to Tumor Survival Through DNA Repair Pathway

Clinical OMICs ٢٠ مايو ٢٠٢٦

Ultra-Short Radiotherapy Schedule for Prostate Cancer Supported by HERMES Trial

Using MRI-guided adaptive radiotherapy, investigators safely condensed prostate cancer treatment into two sessions, potentially reducing patient burden while ma...

Using MRI-guided adaptive radiotherapy, investigators safely condensed prostate cancer treatment into two sessions, potentially reducing patient burden while maintaining tolerable toxicity profiles. The post Ultra-Short Radiotherapy Schedule for Prostate Cancer Supported by HERMES Trial appeared first on Inside Precision Medicine .